Document Classification

Section Type: RESULTS

Text: After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36 % and 34 %, respectively ; hazard ratio, 1. 07 ; 95 % confidence interval [CI], 1. 00 to 1. 15 ; P = 0. 05), the core composite cardiovascular outcome (7. 9 % and 8. 3 %, respectively ; hazard ratio, 0. 94, 95 % CI, 0. 82 to 1. 09 ; P = 0. 43), or the extended composite cardiovascular outcome (14. 2 % and 15. 2 %, respectively ; hazard ratio, 0. 93, 95 % CI, 0. 83 to 1. 03 ; P = 0. 16).